A Taiwanese Research Institute Is Seeking Collaboration for Developing Anti-Globo H ADC, an Oncology Product, Either Through Licensing, Contract Services or Co-development

A Taiwanese non-profit biomedical research institute is developing Anti-Globo H ADC for cancer treatment. The product is currently in the stage of pre-clinical. They are seeking partners for out-licensing, contract services, and co-development in related to the development of anti-Globo H ADC.

About the Technology Antibody-drug conjugate is one of the most important approaches in current cancer drug development. ADC is a tripartite molecule comprising a tumor-specific monoclonal antibody conjugated to a potent cytotoxin via a proprietary stable linking technology. ADC can target the tumor cells through the antibody part by recognizing and binding to a corresponding tumor antigen. After internalization, the ADC will be cleaved or digested in lysosome or endosome, and then the linked cytotoxic drugs are released to kill the cancer cells. The candidate compound of ADC showed great tumor inhibition via a novel target, and belongs to a first-in-class drug for cancer treatment. Application/ Indication: Cancer therapy About the organisation A Taiwanese non-profit biomedical research institute funded both by public and private sectors with a mission to facilitate the development of Taiwan’s biotech industry. The R&D activity of the institute focuses on preclinical development and translational research of new drug development both in biologics/ADC and small molecules. The institute also collaborates with the industry, the academic research institutes, and the hospitals both in Taiwan and in the world to help add value to the technologies, products, and services as well as assist with the business development.